Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma

Dortz, L. Le; Guibert, Sophie de; Bayat, Sahar; Devillers, Anne; Houot, Roch; Rolland, Yan; Cuggia, Marc; Jeune, Florence Le; Bahri, H.; Barge, M; Lamy, Thierry; Garin, Étienne

doi:10.1007/s00259-010-1539-5

Cited by 124 publications

(111 citation statements)

References 14 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Thirdly, 18F-FDG-PET can be used to evaluate treatment response if a patient has 18F-FDG-avid gastrointestinal lesions. In nodal follicular lymphoma, disappearance of 18F-FDG accumulation after completion of treatment has been associated with a favorable outcome [23][24][25] . Although the cost and benefit (e.g., sensitivity, specificity, and patient acceptability) of 18F-FDG-PET vs other modalities, including the combination of CT scanning and endoscopic examinations, remains to be investigated, 18F-FDG-PET represents an option for assessing the therapeutic effect in cases of gastrointestinal involvement of follicular lymphoma.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, nodal and extranodal lesions not detected by other modalities have been identified using 18F-FDG-PET, thereby resulting in a significant advance in lesion management [18][19][20][21][22] . The usefulness of posttreatment 18F-FDG-PET during the follow-up period in cases of follicular lymphoma has also been noted, with positive 18F-FDG accumulation suggesting an adverse outcome [23][24][25] . Consequently, 18F-FDG-PET is considered a valuable tool for the management of nodal follicular lymphoma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement

Iwamuro

Okada²,

Takata³

et al. 2012

WJG

View full text Add to dashboard Cite

AIM:To investigate the capacity for 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) to evaluate patients with gastrointestinal lesions of follicular lymphoma. METHODS:This retrospective case series consisted of 41 patients with follicular lymphoma and gastrointestinal involvement who underwent 18F-FDG-PET and endoscopic evaluations at ten different institutions between November 1996 and October 2011. Data for endoscopic, radiological, and biological examinations performed were retrospectively reviewed from clinical records. A semi-quantitative analysis of 18F-FDG uptake was performed for each involved area by calculating the maximum standardized uptake value (SUVmax). Based on the positivity of 18F-FDG uptake in the gastrointestinal lesions analyzed, patients were subdivided into two groups. To identify potential predictive factors for 18F-FDG positivity, these two groups were compared with respect to gender, age at diagnosis of lymphoma, histopathological grade, pattern of follicular dendritic cells, mitotic rate, clinical stage, soluble interleukin-2 receptor levels detected by 18F-FDG-PET, lactate dehydrogenase (LDH) levels, hemoglobin levels, bone marrow involvement, detectability of gastrointestinal lesions by computed tomography (CT) scanning, and follicular lymphoma international prognostic index (FLIPI) risk. ORIGINAL ARTICLE RESULTS:Involvement of follicular lymphoma in the stomach, duodenum, jejunum, ileum, cecum, colon, and rectum was identified in 1, 34, 6, 3, 2, 3, and 6 patients, respectively. No patient had esophageal involvement. In total, 19/41 (46.3%) patients exhibited true-positive 18F-FDG uptake in the lesions present in their gastrointestinal tract. In contrast, false-negative 18F-FDG uptake was detected in 24 patients (58.5%), while false-positive 18F-FDG uptake was detected in 5 patients (12.2%). In the former case, 2/19 patients had both 18F-FDG-positive lesions and 18F-FDGnegative lesions in the gastrointestinal tract. In patients with 18F-FDG avidity, the SUVmax value of the involved gastrointestinal tract ranged from 2.6 to 17.4 (median: 4.7). For the 18F-FDG-negative (n = 22) and -positive (n = 19) groups, there were no differences in the male to female ratios (10/12 vs 4/15, P = 0.186), patient age (63.6 ± 2.4 years vs 60.1 ± 2.6 years, P = 0.323), presence of histopathological grade 1 vs 2 (20/2 and 17/2, P = 1.000), follicular dendritic cell pattern (duodenal/nodal: 13/5 vs 10/3, P = 1.000), mitotic rate (low/ partly high, 14/1 vs 10/3, P = 0.311), clinical stage according to the Ann Arbor system (stages ⅠE and ⅡE/ other, 15/7 vs 15/4, P = 0.499), clinical stage according to the Lugano system (stages Ⅰ and Ⅱ-1/other, 14/8 vs 14/5, P = 0.489), soluble interleukin-2 receptor levels (495 ± 78 vs 402 ± 83, P = 0.884), LDH levels (188 ± 7 vs 183 ± 8, P = 0.749), hemoglobin levels (13.5 ± 0.3 vs 12.8 ± 0.4, P = 0.197), bone marrow involvement (positive/negative, 1/8 vs 1/10, P = 1.000), detectability by CT scanning (positive/negative, 1/16 vs 4/13, P = 0.335...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement

Iwamuro

Okada²,

Takata³

et al. 2012

WJG

View full text Add to dashboard Cite

show abstract

“…Published literature includes 10 retrospective analyses [9][10][11][12][13][14][15][16][17][18] and 1 prospective one [19]: pooled analysis of 356 patients revealed that 24% were upstaged from Stage I-II to Stage III-IV. Baseline PET also showed to have a high prognostic value, irrespective of FLIPI [10,11,17,19]. No study reported the clinical outcomes in patients in which the therapy was adjusted according to a PET-staged disease.…”

Section: Issue 1: Staging (Consensus-based Recommendations)mentioning

confidence: 99%

SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma

et al. 2013

View full text Add to dashboard Cite

By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issued in 2006 from SIE, SIES, and GITMO group. We confirmed our recommendation to frontline chemoimmunotherapy in patients with Stage III-IV disease and/or high tumor burden. Maintenance rituximab was also recommended in responding patients. In patients relapsing after an interval longer than 12 months from frontline therapy, we recommended chemoimmunotherapy with non cross-resistant regimens followed by rituximab maintenance. High dose chemotherapy followed by hematopoietic stem cell transplant was recommended for young fit patients who achieve a response after salvage chemoimmunotherapy. Am. J. Hematol. 88:185-192, 2013. V

show abstract

“…PET scanning proved to be effective in at least four major studies on large series of patients included in prospective clinical trials [Le Dortz et al 2010;Trotman et al 2011;Lopci et al 2012;Dupuis et al 2012]. MRD monitoring also proved to be a powerful outcome predictor in FL in a…”

Section: Introductionmentioning

confidence: 99%

Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma

Lobetti-Bodoni

Mantoan

Monitillo

et al. 2013

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Abstract:The identification of patients at high risk of relapse is a critical goal of modern translational research in oncohematology. Minimal residual disease (MRD) detection by polymerase chain reaction-based methods is routinely employed in the management of patients with acute lymphoblastic leukemia. Current knowledge indicates that it is also a useful prognostic tool in several mature lymphoproliferative disorders and particularly in follicular lymphoma (FL). Based on this evidence clinical trials employing MRD-based risk stratification are currently ongoing in FL. In this review the 'state of the art' of MRD evaluation in FL is discussed. A short description of technical issues and recent methodological advances is provided. Then, the bulk of the review focuses on critical take-home messages for clinicians working in the field. Finally, we discuss future perspectives of MRD detection and more generally outcome prediction in FL.

show abstract

Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma

Abstract: FDG PET/CT is useful for staging and assessing the prognosis and therapeutic response of patients with follicular lymphoma.

Cited by 124 publications

References 14 publications

Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement

Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement

SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma

Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma

Contact Info

Product

Resources

About